Combination Therapy
Approved for: NSCLC
Durvalumab (Imfinzi) is a FDA-approved Combination Therapy for Non-small cell lung cancer (NSCLC). It is used in adults with stage III NSCLC that cannot be removed by surgery and did not get worse after platinum chemotherapy and radiation therapy.
